Claritin Label May Not Need Physician Diagnosis Statement – Consultant
This article was originally published in The Tan Sheet
Executive Summary
Physician diagnosis instructions on OTC Claritin labeling would not be necessary if the second generation, non-sedating antihistamine is approved by FDA for a general hives or urticaria claim, according to William Rosenberg, MD, University of Tennessee
You may also be interested in...
Claritin OTC Approval For CIU Would Reduce Off-Label Drug Use – Schering
Failure to approve Claritin OTC for chronic idiopathic urticaria would perpetuate off-label use of non-prescription drugs to treat hives, Schering-Plough told FDA's Nonprescription Drugs Advisory Committee at a meeting in Bethesda, Md. April 22
Loratadine Clinical Trials On General Hives Suggested By NDAC Members
An OTC switch of Schering-Plough's non-sedating antihistamine Claritin for general hives would require data from an evidence-based study of acute urticaria, Jesse Joad, MD, UC-Davis Medical Center, asserted at a meeting of FDA's Nonprescription Drugs Advisory Committee April 22
Loratadine Clinical Trials On General Hives Suggested By NDAC Members
An OTC switch of Schering-Plough's non-sedating antihistamine Claritin for general hives would require data from an evidence-based study of acute urticaria, Jesse Joad, MD, UC-Davis Medical Center, asserted at a meeting of FDA's Nonprescription Drugs Advisory Committee April 22